Inhibikase Therapeutics Inc
NASDAQ:IKT
Income Statement
Earnings Waterfall
Inhibikase Therapeutics Inc
Revenue
|
260.5k
USD
|
Operating Expenses
|
-20.4m
USD
|
Operating Income
|
-20.1m
USD
|
Other Expenses
|
1.1m
USD
|
Net Income
|
-19m
USD
|
Income Statement
Inhibikase Therapeutics Inc
Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||||||||||||
Revenue |
4
N/A
|
2
-52%
|
2
+9%
|
2
+6%
|
1
-50%
|
1
-29%
|
1
+6%
|
1
-9%
|
1
-9%
|
2
+163%
|
3
+62%
|
3
+10%
|
3
-5%
|
2
-44%
|
0
-78%
|
0
-82%
|
0
+71%
|
0
+17%
|
0
+79%
|
0
+28%
|
0
-19%
|
|
Operating Income | ||||||||||||||||||||||
Operating Expenses |
(6)
|
(5)
|
(7)
|
(9)
|
(7)
|
(5)
|
(3)
|
(3)
|
(4)
|
(7)
|
(10)
|
(14)
|
(18)
|
(19)
|
(19)
|
(19)
|
(18)
|
(18)
|
(20)
|
(20)
|
(20)
|
|
Selling, General & Administrative |
(3)
|
(2)
|
(4)
|
(5)
|
(4)
|
(4)
|
(2)
|
(2)
|
(3)
|
(4)
|
(5)
|
(6)
|
(7)
|
(7)
|
(7)
|
(7)
|
(6)
|
(6)
|
(7)
|
(7)
|
(7)
|
|
Research & Development |
(4)
|
(3)
|
(3)
|
(4)
|
(3)
|
(1)
|
(1)
|
(1)
|
(1)
|
(3)
|
(5)
|
(8)
|
(11)
|
(12)
|
(13)
|
(12)
|
(12)
|
(12)
|
(13)
|
(14)
|
(14)
|
|
Operating Income |
(2)
N/A
|
(3)
-41%
|
(5)
-78%
|
(7)
-23%
|
(6)
+13%
|
(5)
+21%
|
(3)
+43%
|
(2)
+21%
|
(3)
-39%
|
(5)
-74%
|
(7)
-45%
|
(11)
-54%
|
(15)
-35%
|
(17)
-14%
|
(19)
-12%
|
(19)
0%
|
(18)
+4%
|
(18)
0%
|
(20)
-9%
|
(20)
-1%
|
(20)
0%
|
|
Pre-Tax Income | ||||||||||||||||||||||
Interest Income Expense |
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
|
Pre-Tax Income |
(2)
N/A
|
(3)
-40%
|
(5)
-78%
|
(7)
-23%
|
(6)
+13%
|
(5)
+21%
|
(3)
+42%
|
(2)
+21%
|
(3)
-38%
|
(5)
-73%
|
(7)
-45%
|
(11)
-53%
|
(15)
-35%
|
(17)
-14%
|
(19)
-12%
|
(19)
0%
|
(18)
+4%
|
(18)
+1%
|
(19)
-6%
|
(19)
-1%
|
(19)
+1%
|
|
Net Income | ||||||||||||||||||||||
Income from Continuing Operations |
(2)
|
(3)
|
(5)
|
(7)
|
(6)
|
(5)
|
(3)
|
(2)
|
(3)
|
(5)
|
(7)
|
(11)
|
(15)
|
(17)
|
(19)
|
(19)
|
(18)
|
(18)
|
(19)
|
(19)
|
(19)
|
|
Net Income (Common) |
(2)
N/A
|
(3)
-40%
|
(5)
-78%
|
(7)
-23%
|
(6)
+13%
|
(5)
+21%
|
(3)
+42%
|
(2)
+21%
|
(3)
-38%
|
(5)
-73%
|
(7)
-45%
|
(11)
-53%
|
(15)
-35%
|
(17)
-14%
|
(19)
-12%
|
(19)
0%
|
(18)
+4%
|
(18)
+1%
|
(19)
-6%
|
(19)
-1%
|
(19)
+1%
|
|
EPS (Diluted) |
-1.41
N/A
|
-1.91
-35%
|
-4.56
-139%
|
-4.81
-5%
|
-3.67
+24%
|
-2.9
+21%
|
-2.23
+23%
|
-1.51
+32%
|
-2.08
-38%
|
-2.94
-41%
|
-1.7
+42%
|
-2.61
-54%
|
-3.53
-35%
|
-4
-13%
|
-4.47
-12%
|
-4.47
N/A
|
-4.3
+4%
|
-3.89
+10%
|
-3.63
+7%
|
-3.58
+1%
|
-3.57
+0%
|